ATTR-CM clinical trials at UCSF

1 research study open to eligible people

ATTR-CM is a heart disease where abnormal transthyretin protein builds up in the heart. UCSF is enrolling people in a global study that follows the disease over time. The study records symptoms, heart scans, and blood tests to track changes.

Showing trials for

  • Patients With Transthyretin (ATTR) Amyloidosis

    open to eligible people ages 18-130

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    San Francisco, California and other locations

Last updated: